Core Viewpoint - 10x Genomics reported quarterly earnings of $0.28 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.35 per share, marking an earnings surprise of +180.00% [1][2] Financial Performance - The company posted revenues of $172.91 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 24.00% and showing an increase from $153.1 million in the same quarter last year [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - 10x Genomics shares have declined approximately 11.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $144.82 million, and for the current fiscal year, it is -$1.12 on revenues of $593.29 million [7] - The trend of estimate revisions for 10x Genomics was favorable ahead of the earnings release, suggesting potential positive movements in stock performance [6] Industry Context - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Group 1 - Doximity reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of +16.13% [1] - The company achieved revenues of $145.91 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.47%, and up from $126.68 million year-over-year [2] - Doximity has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 8.9% since the beginning of the year, compared to the S&P 500's gain of 7.9% [3] - The future performance of Doximity's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.35 on revenues of $150.43 million, and for the current fiscal year, it is $1.46 on revenues of $625.72 million [7] Group 3 - The Medical Info Systems industry, to which Doximity belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Doximity's stock performance [5][6]

Core Insights - Enovis (ENOV) reported quarterly earnings of $0.79 per share, exceeding the Zacks Consensus Estimate of $0.74 per share, and up from $0.62 per share a year ago, representing an earnings surprise of +6.76% [1] - The company achieved revenues of $564.55 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.83% and increasing from $525.16 million year-over-year [2] - Enovis has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was +9.46%, with actual earnings of $0.81 per share against an expectation of $0.74 [1] - The current consensus EPS estimate for the upcoming quarter is $0.66, with expected revenues of $535.09 million, and for the current fiscal year, the EPS estimate is $3.04 on revenues of $2.24 billion [7] Stock Performance and Outlook - Enovis shares have declined approximately 41.3% year-to-date, contrasting with the S&P 500's gain of 7.9% [3] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Enovis belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Privia Health reported quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.05 per share, and down from $0.03 per share a year ago, representing an earnings surprise of -60.00% [1] - The company posted revenues of $521.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.24%, compared to year-ago revenues of $422.33 million [2] - Privia Health has topped consensus revenue estimates four times over the last four quarters [2] Group 2 - The stock's immediate price movement will depend on management's commentary on the earnings call and future earnings expectations [3] - Privia Health shares have added about 1.2% since the beginning of the year, underperforming the S&P 500's gain of 7.9% [3] Group 3 - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $474.01 million, and $0.21 on revenues of $1.91 billion for the current fiscal year [7] - The estimate revisions trend for Privia Health was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 4 - The Medical Info Systems industry, to which Privia Health belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook [8]

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.92%. A quarter ago, it was expected that this company would post a loss of $0.71 per share when it actually produced a loss of $0.82, delivering a surprise of -15.49%.Over the last four quarters, the company has su ...

Claritev Corporation (CTEV) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $2.69 per share. This compares to a loss of $1.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +111.90%. A quarter ago, it was expected that this company would post a loss of $2.2 per share when it actually produced a loss of $3.43, delivering a surprise of -55.91%. Over the last four quarters, ...

分组1 - MDxHealth SA reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, but an improvement from a loss of $0.31 per share a year ago, indicating a surprise of -15.38% [1] - The company posted revenues of $26.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02% and showing an increase from $22.16 million in the same quarter last year [2] - MDxHealth SA shares have increased by approximately 4.2% since the beginning of the year, while the S&P 500 has gained 7.6%, indicating underperformance relative to the broader market [3] 分组2 - The earnings outlook for MDxHealth SA is uncertain, with current consensus EPS estimates of -$0.11 for the coming quarter and -$0.52 for the current fiscal year, alongside expected revenues of $27.8 million and $108.5 million respectively [7] - The Zacks Industry Rank places the Medical Info Systems sector in the top 29% of over 250 Zacks industries, suggesting that companies in the top half of the rankings tend to outperform those in the bottom half by more than 2 to 1 [8] - The estimate revisions trend for MDxHealth SA was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6]

Group 1 - American Well Corporation (AMWL) reported a quarterly loss of $1.24 per share, which was better than the Zacks Consensus Estimate of a loss of $1.84, and an improvement from a loss of $3.36 per share a year ago, resulting in an earnings surprise of +32.61% [1] - The company posted revenues of $70.9 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 11.42%, and showing an increase from year-ago revenues of $62.79 million [2] - American Well has surpassed consensus EPS estimates four times over the last four quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has underperformed the market, losing about 2.9% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.98 on revenues of $63.11 million, and for the current fiscal year, it is -$6.91 on revenues of $255.84 million [7] - The Medical Info Systems industry, to which American Well belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced earnings of $0.05, delivering a surprise of +171.43%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Clover Hea ...

Company Performance - Inspire Medical Systems reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and up from $0.32 per share a year ago [1] - The earnings surprise for this quarter was +104.55%, following a previous surprise of +143.48% when the company reported earnings of $0.1 per share against an expected loss of $0.23 per share [2] - The company achieved revenues of $217.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.95% and increasing from $195.88 million year-over-year [3] Market Outlook - Despite the positive earnings report, Inspire shares have declined approximately 32% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [4] - The future performance of Inspire's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [5][6] - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $239.64 million, and for the current fiscal year, it is $2.26 on revenues of $949.14 million [8] Industry Context - The Medical Info Systems industry, to which Inspire belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9] - The performance of Inspire's stock may also be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]